Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Group A:~* Males and females aged 18 to 80 yrs~* Diabetes mellitus type 1 or 2~* Haemoglobin level above the treatment threshold level (as described in the drug description)~* Receiving no darbepoetin alfa treatment~* Best Corrected Visual Acuity (BCVA) better than 20/200~* No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.~Group B:~* Males and females aged 18 to 80 yrs~* Diabetes mellitus type 1 or2~* Anaemia (due to renal failure), haemoglobin level under the treatment threshold level before the initialisation of the therapy (as described in the drug label)~* Starting to receive darbepoetin alfa treatment (darbepoetin alfa, Aranesp, Amgen)~* BCVA better than 20/200~* No clinically significant macular edema (CSME) or CSME already treated with laser photocoagulation.~Exclusion Criteria:~* History of retinal disease other than DR~* History of intraocular surgery, including laser treatment in the past 4 month~* A major change in the insulin treatment of the patient in the past 4 month or during the follow up period.~* Inability to communicate in German or English~* Dementia; inability to follow commands~* Epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
- B (Type: None): Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.

Based on this trial design, predict the completion outcome and termination type (if applicable).